Skip to main content
editorial
. 2018 Dec 11;13(2):103–109. doi: 10.1007/s12072-018-9915-5

Table 3.

APASL recommendation for the treatment regimens of patients with HCV and severe impaired renal function

HCV GTs Regimens Treatment duration (weeks) Grading of evidence and recommendations (disease status)
GT1a, GT1b, GT4 Elbasvir (50 mg daily)/grazoprevir (100 mg daily) 12 A-1 (CKD 3b/4/5 or hemodialysis)
All GTs Glecaprevir (300 mg daily)/pibrentasvir (120 mg daily) 8–16 A-1 (CKD 3b/4/5 or hemodialysis)
GT1b Daclatasvir (60 mg daily)/asunaprevir (200 mg daily) 24 B-2 (CKD 3b/4/5 or hemodialysis)
All GTs Sofosbuvir (400 mg daily)/daclatasvir (60 mg daily) under close monitoring 12 B-2 (CKD 3b/4/5 or hemodialysis)
GT1 Sofosbuvir (400 mg daily)/ledipasvir (90 mg daily) under close monitoring 12 B-2 (CKD 3b/4/5 or hemodialysis)

Grading of evidence and recommendations are shown in Suppl. Table 1

GTs genotypes